This activity is supported by educational grants from GlaxoSmithKline and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Tuesday, April 27, 2021
8:30 AM – 10:00 AM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

• Overview of multiple myeloma (MM) incidence and prognosis, patient signs and symptoms at presentation and diagnostic/staging considerations
• Selection of induction therapy for patients with standard- and high-risk MM who are eligible and ineligible for transplant; clinical and biologic factors in the selection of maintenance therapy after induction (eg, high-risk features, t(4;14), response to induction therapy)
• Importance of prior therapeutic exposure, disease-free interval, cytogenetic status and symptomatology in therapeutic decision-making for patients with relapsed, progressive disease
• Balancing benefits and side effects in the selection and sequencing of treatments for multiple regimen-relapsed MM; review of recently approved agents for relapsed/refractory MM (ie, isatuximab, belantamab mafodotin, selinexor and melflufen), including mechanism of action, efficacy, and incidence, type and management of associated adverse events
• Compositional and mechanistic variations among the recently approved and developmental BCMA-targeted chimeric antigen receptor (CAR) T-cell therapies for MM, including idecabtagene vicleucel; indications for use and unique practical considerations for administration to patients.
• Other promising agents and strategies under investigation for the treatment of MM

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate published research findings documenting disparities in the incidence, treatment and mortality of multiple myeloma (MM) among various ethnic and racial groups in order to identify individuals at risk for poor outcomes.
• Consider the prognostic implications of unequal access to care among African Americans and other minority groups with MM, and employ available resources and strategies to help patients overcome barriers to appropriate healthcare.
• Customize induction and subsequent maintenance therapeutic approaches for patients with MM eligible or ineligible for stem cell transplant, considering recently presented clinical trial findings and patient- and disease-related factors, including cytogenetic profile.
• Discuss new and existing research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and evaluate how this strategy should be integrated into the clinical management of this disease.
• Understand how preexisting medical conditions can affect a patient’s eligibility for MM-specific therapeutic modalities, and adapt treatment recommendations to account for comorbidities.
• Appreciate the implications of emerging research data and other clinical, social and economic factors for the selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory (R/R) MM.
• Evaluate available and emerging efficacy and safety data with CAR (chimeric antigen receptor) T-cell therapies directed at BCMA (B-cell maturation antigen), and identify patients with R/R MM for whom this approach may be appropriate as part of a clinical research study.
• Educate patients about the side effects associated with approved therapies commonly used in the management of MM, and provide preventive strategies to reduce or ameliorate these toxicities.
• Assess the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel and investigational approaches for MM, and develop strategies to effectively counsel patients of various racial, ethnic and socioeconomic backgrounds about the potential benefits of participation in research protocols.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2021/MM/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Kumar – Consulting/Advisory Board: Antengene, BeiGene Ltd, Oncopeptides; Consulting/Advisory Board (no personal payments): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Takeda Oncology; Research Funding for Clinical Trials to the Institution: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio. Dr Lonial – Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology. Dr Richardson – Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Secura Bio, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Oncopeptides, Takeda Oncology.

CONTRIBUTING NURSES — Ms Gleason had no relevant conflicts of interest to disclose. The following nurse practitioners reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ms Mangan — Consulting Agreements: GlaxoSmithKline, Merck; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Oncology. Dr Richards — Consulting Agreements: Celgene Corporation, GlaxoSmithKline, Sanofi Genzyme, Takeda Oncology.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from GlaxoSmithKline and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.